Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.79 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1589823 | 0.91 | P2RX7 (0.82) | P2RX7TRPV1POLBSCDKDM4E | |
| Hydrochloric Acid SCHEMBL1590577 | 0.91 | P2RX7 (0.81) | P2RX7TRPV1POLBSCDKDM4E | |
| SCHEMBL12702803 | 0.90 | P2RX7 (0.85) | P2RX7TRPV1POLB | |
| SCHEMBL1590510 | 0.89 | P2RX7 (0.62) | P2RX7POLBKDM4E | |
| SCHEMBL1590086 | 0.89 | P2RX7 (0.62) | P2RX7TRPV1POLBENPP2KDM4E | |
| SCHEMBL1590156 | 0.89 | P2RX7 (1.00) | P2RX7TRPV1POLBSCDKDM4E | |
| SCHEMBL1590519 | 0.87 | P2RX7 (0.78) | P2RX7TRPV1POLBKDM4EMAPT | |
| SCHEMBL13047346 | 0.87 | P2RX7 (0.81) | P2RX7TRPV1POLBSCDKDM4E | |
| SCHEMBL3747851 | 0.87 | P2RX7 (0.81) | P2RX7TRPV1POLBMAPT | |
| SCHEMBL1590713 | 0.87 | P2RX7 (0.59) | P2RX7TRPV1POLBSCDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2011-04-21 | — | — | US | claimed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | claimed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | claimed |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2011-04-21 | — | — | US | disclosed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885TRPV1 19/4885POLB 3676/4885 |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885TRPV1 19/4885POLB 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.